CYCN · As filed with the SEC
Korsana Biosciences income statement, by fiscal year
The statement as Korsana Biosciences presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Operations and Comprehensive Loss · USD
| USD | FY2025 Year ended Dec 31, 2025 | FY2024 Year ended Dec 31, 2024 |
|---|---|---|
| Revenues: | ||
| Total revenues | 2,074,000 | 2,000,000 |
| Revenue from license agreement | 1,000,000 | 1,750,000 |
| Revenue from purchase agreement | 800,000 | 0 |
| Revenue from option agreement | 274,000 | 250,000 |
| Cost and expenses: | ||
| Research and development | 959,000 | 286,000 |
| General and administrative | 6,088,000 | 5,342,000 |
| Total cost and expenses | 7,047,000 | 5,628,000 |
| Loss from operations | (4,973,000) | (3,628,000) |
| Other income, net | ||
| Interest income | 128,000 | 208,000 |
| Gain from settlement of account payable | 0 | 363,000 |
| Total other income, net | 1,445,000 | 571,000 |
| Gain from insurance recovery | 1,317,000 | 0 |
| Net loss | (3,528,000) | (3,057,000) |
| Net loss per share: | ||
| Net loss per share - Basic | (1.11) | (1.21) |
| Net loss per share - Diluted | (1.11) | (1.21) |
| Weighted average shares used in calculating: | ||
| Basic shares | 3,181,000 | 2,518,000 |
| Diluted shares | 3,181,000 | 2,518,000 |
| Other comprehensive loss: | ||
| Net loss | (3,528,000) | (3,057,000) |
| Other comprehensive loss: | ||
| Foreign currency translation adjustment loss | 0 | (6,000) |
| Comprehensive loss | (3,528,000) | (3,063,000) |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.